Accumulated evidence shows that the ACE-AngII-AT1 axis of the renin-angiotensin system (RAS) is markedly activated in chronic heart failure (CHF). Recent studies provide information that Angiotensin (Ang)-(1–7), a metabolite of AngII, counteracts the effects of AngII. However, this balance between AngII and Ang-(1–7) is still little understood in CHF. We investigated the effects of exercise training on circulating and skeletal muscle RAS in the ischemic model of CHF.
Male Wistar rats underwent left coronary artery ligation or a Sham operation. They were divided into four groups: 1) Sedentary Sham (Sham-S), 2) exercise-trained Sham (Sham-Ex), sedentary CHF (CHF-S), and exercise-trained CHF (CHF-Ex). Angiotensin concentrations and ACE and ACE2 activity in the circulation and skeletal muscle (soleus and plantaris) were quantified. Skeletal muscle ACE and ACE2 protein expression, and AT1, AT2, and Mas receptor gene expression were also evaluated. CHF reduced ACE2 serum activity. Exercise training restored ACE2 and reduced ACE activity in CHF. Exercise training reduced plasma AngII concentration in both Sham and CHF rats and increased the Ang-(1–7)/AngII ratio in CHF rats. CHF and exercise training did not change skeletal muscle ACE and ACE2 activity and protein expression. CHF increased AngII levels in both soleus and plantaris muscle, and exercise training normalized them. Exercise training increased Ang-(1–7) in the plantaris muscle of CHF rats. The AT1 receptor was only increased in the soleus muscle of CHF rats, and exercise training normalized it. Exercise training increased the expression of the Mas receptor in the soleus muscle of both exercise-trained groups, and normalized it in plantaris muscle.
Citation: Gomes-Santos IL, Fernandes T, Couto GK, Ferreira-Filho JCA, Salemi VMC, Fernandes FB, et al. (2014) Effects of Exercise Training on Circulating and Skeletal Muscle Renin-Angiotensin System in Chronic Heart Failure Rats. PLoS ONE 9(5): e98012. https://doi.org/10.1371/journal.pone.0098012
Editor: Edward F. Plow, Lerner Research Institute, United States of America
Received: November 18, 2013; Accepted: April 28, 2014; Published: May 23, 2014
Copyright: © 2014 Gomes-Santos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP-2010/50048-1) and, in part, by Fundação Zerbini. IL Gomes-Santos was supported by Coordenadoria de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). PC Brum, DE Casarini, LV Rossoni, EM Oliveira and CE Negrao are research fellows at Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The fact that Dra. Dulce Casarini is a PLOS ONE Editorial Board Member does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Increased renin angiotensin system (RAS) has been consistently documented in chronic heart failure (CHF). Plasma Angiotensin (Ang) II levels are increased in CHF –. Likewise, RAS elevation in the heart, kidneys, and brain has been reported in CHF –. This scenario shows that CHF is characterized by overall RAS activation.
The classic RAS cascade depends on ACE-mediated conversion of AngI into AngII, an octapeptide binding to AT1 receptor. This ACE-AngII-AT1 axis contributes to cardiac remodeling , , high sympathetic activity , , and impaired vasodilation  in CHF. In addition, RAS exacerbation plays a role in skeletal myopathy, including reactive oxygen species generation, protein degradation, and apoptosis –. Recent studies provide evidence of an endogenous RAS axis that counterbalances the ACE-AngII-AT1 effects. ACE2, an ACE homolog enzyme , , metabolizes AngII into the heptapeptide Ang-(1–7) , which in turn binds to the Mas receptor . This ACE2-Ang-(1–7)-Mas axis causes vasodilation and improves skeletal muscle metabolism , . In addition, ACE2-Ang-(1–7)-Mas axis has antifibrotic and antiapoptotic properties, opposing the deleterious effects of ACE-AngII-AT1 overactivity .
Previous studies have shown that exercise training is a remarkable strategy in the treatment of CHF. This therapy reduces sympathetic nerve activity and vasoconstriction , . In addition, exercise training significantly increases exercise tolerance and quality of life in CHF patients . Effects of exercise training on RAS have also been reported. Exercise training reduces plasma AngII levels , . In the cardiac muscle, exercise reduces ACE concentration, which may contribute to the reduction in hypertrophy and collagen deposition in rats with myocardial infarction . More recently, we found a decrease in ACE and AngII concentrations and an increase in ACE2 and Ang-(1–7) concentration in cardiac muscle in exercise-trained rats . In addition, exercise training has been shown to increase cardiac Ang-(1–7) in spontaneous hypertensive rats  and to normalize brain ACE and ACE2 expression in CHF rabbits . However, the effects of exercise training on RAS in skeletal muscle are unknown.
To improve the understanding regarding the role of exercise training on circulating and skeletal muscle RAS, we investigated the effects of exercise training on ACE-AngII-AT1 and ACE2-Ang-(1–7)-Mas axis in rats with CHF. Our hypotheses were that: 1) Exercise training would shift the balance of RAS towards the ACE2-Ang-(1–7)-Mas axis; 2) The changes in skeletal muscle RAS would be independent of those observed in the circulation; and 3) The effects of exercise training on skeletal muscle would be influenced by muscle metabolic characteristic.
Two-month-old, male, Wistar rats from the Multidisciplinary Center for Biological Investigation on Laboratory Animal Science (CEMIB), University of Campinas, underwent surgical occlusion of the main descending branch of the left coronary artery or fictitious myocardial infarction (Sham). After a 4-week period, they were subdivided into four groups: 1) Sedentary sham-operated (Sham-S, n = 10); 2) exercise-trained sham-operated (Sham-Ex, n = 10), 3) sedentary chronic heart failure (CHF-S, n = 12); and 4) exercise-trained chronic heart failure (CHF-Ex, n = 12). Then, basal echocardiography was performed and peak oxygen consumption was measured. Finally, exercise training or follow-up began (Experimental protocol, Fig. 1). The rats were kept 3–4 per cage in a temperature-controlled room with a 12∶12-hour light-dark cycle. They were fed with a standard laboratory diet and water ad libitum. The study was approved by the Scientific Committee of the Heart Institute (InCor-HCFMUSP) and Ethical Committee for Research Protocols of the University of São Paulo Medical School (CAPPesq 149/09). The study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, USA. The surgery and echocardiography was performed under anesthesia, and all efforts were made to minimize suffering.
Myocardial Infarction Induction
The rats were anesthetized with a single injection of ketamine (50 mg.kg−1 body weight, Parke-Davis) and xylazine (10 mg.kg−1 body weight, Bayer). Then, the heart was exposed through a left intercostal thoracotomy. The left coronary artery was looped by a single nylon suture (7-0) ∼1 mm. The main descending branch was permanently occluded, which resulted in myocardial infarction and, subsequently, CHF. Finally, the heart was quickly repositioned into the chest .
Cardiac Function Assessment
The left ventricular evaluations were performed in anesthetized rats at baseline (4 weeks after surgery) and at the end of study (12 weeks after surgery). Echocardiographic studies were performed with Acuson equipment (Siemens, Mountain View, CA, EUA) with a 13 MHz transducer. Left ventricular dimensions were measured in the M-mode, and left ventricular fractional shortening (FS) was calculated by the formula FS = [(EDD/ESD)/EDD]x100, where EDD means left ventricular end-diastolic dimension and ESD left ventricular end-systolic dimension. Ejection fraction (EF) was assessed by Simpson's biplane method at 2-dimensional parasternal long-axis view. All the analyses were conducted according to the American Society of Echocardiography guidelines .
Twenty-four hours after echocardiographic assessment, exercise capacity was measured, which was conducted at baseline (4 weeks after surgery) and at the end of study (12 weeks after surgery). The rats were previously adapted to treadmill exercise before testing. On a treadmill inside of a metabolic chamber coupled to a gas analyzer, rats ran progressively until exhaustion, starting at 6 m.min−1 and 3 m.min−1 increments every 3 minutes. Peak oxygen uptake (peak VO2) was defined as the highest VO2 achieved before exhaustion, calculated by the formula peak VO2 = [(pO2 ambient - pO2 at stage)xF]/m, where pO2 is the partial oxygen pressure measured in the ambient before testing and continuously through each stage inside the chamber, F is the airflow through the chamber (3500 mL.min−1), and m is the rat's body mass in kilogram, adapted from Brooks and collaborators . This procedure also provided running distance, in meters.
Twenty-hour hours after exercise capacity assessment at baseline, exercise training began. Continuous moderate aerobic exercise training was conducted on a treadmill for 60 minutes at 60% of peak VO2, 5 days a week for 8 weeks as described earlier . At the end of the fourth week, training rats underwent another exercise test to adjust the intensity of exercise training. All rats kept sedentary were exposed to treadmill running for 5 minutes, once a week, to maintain their running skills.
Sacrifice and Collection of Blood and Tissues
Twenty-four hours after peak V02 assessment at the end of the experimental protocol, the rats were quickly sacrificed by decapitation with no prior anesthesia to avoid influences on RAS cascade. Trunk blood was immediately collected into dry (for serum) and cooled tubes (for plasma) with proteases inhibitor cocktail (miniComplete, Roche, USA), separated from total blood as soon as possible, and frozen for posterior analysis. The tissue samples were quickly excised, weighted, and frozen in liquid nitrogen. Thereafter, the samples were stored in a freezer −80° for later analysis.
ACE and ACE2 Activity Assay
ACE activity was determined in serum, and in skeletal soleus and plantaris muscle by using fluorescent substrates . Frozen skeletal muscle samples were homogenized in 0.1 M Tris-HCl buffer pH 7.0, containing 50 mM NaCl and centrifuged at 1,000×g for 10 minutes. The assays were performed at 37°C in 0.1 M Tris-HCl buffer pH 7.0, containing 50 mM NaCl and 10 µM ZnCl2, and captopril 0.5 µL as inhibitor in negative samples. The hydrolysis rate of the intramolecularly quenched fluorogenic substrate Abz-FRK-(Dnp)P-OH (10 uM) incubated with aliquots of homogenate and serum for 30 minutes at 37°C was assessed to obtain ACE enzymatic activity (420 nm λem and 320 nm λex, read in 90 cycles). ACE2 activity was determined by the same method described above. However, Abz-APK(Dnp)-OH was used as the fluorescent peptide, in 0.2 M Tris-HCl buffer, 200 mM NaCl, pH 7.5, and DX600 1 mM as the inhibitor. ACE and ACE2 activity are expressed as uF.min−1.mg−1 of skeletal muscle protein concentration, or uF.min−1.mL−1 of serum.
Quantification of Angiotensins
The determination of AngI, AngII, and Ang-(1–7) was quantified by High Performance Liquid Chromatography (HPLC), as previously demonstrated by our group . After centrifugation (10,000×g, 4°C, 20 min), 1 mL of plasma was filtered in Oasis C18 columns (Waters, USA), previously activated with methanol (5 mL), tetrahydrofuran (5 mL), hexane (5 mL), methanol (5 mL), and water (10 mL). After activation, the samples were applied into the columns, washed with water and eluted in ethanol/acetic acid/water in the proportion 90%/4%/6%. The eluted fractions were lyophilized and resuspended in 500 µL of mobile phase A (5% acetonitrile in 0.1% orthophosphoric acid) and filtered with 0.22 mm membrane for analysis (HPLC, Shimadzu System, Japan). The angiotensin of each sample was separated on a reversed phase column ODS Aquapor 300 (250×4.6 mm), 7 µ (PerkinElmer's Browlee Columns, USA) using the gradient from 5–35% of mobile phase B (95% acetonitrile in 0.1% phosphoric acid) under a flow of 1.5 mL.min−1 for 40 minutes. The angiotensins were identified by comparing them with the retention time of standard angiotensins. Results are expressed as pmol.mL−1 of plasma. Skeletal muscle soleus and plantaris samples were weighted and homogenized in 100 mM sodium phosphate buffer pH 7.2, 340 mM sucrose and 300 mM NaCl and protease inhibitor cocktail (Roche, USA). The samples were centrifuged and followed the same sequence as described for plasma angiotensins. Results are expressed as pmol.g−1 of tissue.
Quantification of Protein Expression
The protein expression of ACE and ACE2 in the soleus and plantaris muscles was analyzed using western blot. The frozen samples were homogenized in cell lyses buffer containing 100 mM Tris-HCl, 50 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail (1∶100, Sigma-Aldrich, USA). After centrifugation (10,000 × g, 4°C, 10 min), the pellet was discarded, and the samples were loaded (Laemmli 1∶1, Sigma-Aldrich, USA) and underwent SDS-PAGE in 10% polyacrylamide gels. Equal loading of samples (30 µg) were applied for electrophoresis, and proteins were electro-transferred to nitrocellulose membrane (BioRad Biosciences, USA). The blot membrane was then incubated in a blocking buffer (5% BSA, 10 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween 20) for 2 hours at room temperature and then incubated overnight at 4°C with mouse anti-ACE (ab11734, 1∶100, Abcam, USA) and rabbit anti-ACE2 (sc-20998 1∶200, Santa Cruz, USA). Binding of the primary antibody was detected with the use of peroxidase-conjugated secondary antibodies, and enhanced chemiluminescence reagents (Amersham Biosciences, USA) were used to visualize the autoradiography. Quantification blot analyses were performed using Image-J software (National Institute of Health, USA), normalized to relative changes in mouse anti-GAPDH (ab9484, 1∶5000, Abcam, USA).
RNA Isolation and mRNA Quantification
Frozen skeletal muscle samples were homogenized in Trizol, and RNA was isolated according to manufacturer's instructions (Invitrogen Life Technologies, USA). Following extraction, total RNA concentration was quantified using NanoDrop Spectrophotometer (Nano-Drop Technologies, USA) and checked for integrity by EtBr agarose gel electrophoresis. cDNA was synthetized using reverse transcriptase at 70°C for 10 minutes, incubation at 42°C for 60 minutes, and 95°C for 10 minutes. The mRNA expression was assessed by oligonucleotides primers (Exxtend, Brazil) for analysis of the genes AT1a (Sense: 5′-CAC AAC CCT CCC AGA AAG TG-3′; antisense:5′-AGG GCC ATT TTG TTT TTC TG-3′), AT2 (Sense: 5′- GAA CAG AAT TAC CCG TGA CC-3′; antisense: 5′- ATG AAT GCC AAC ACA ACA GC-3′), Mas (Sense: 5′-GAC CAG CCC ACA GTT ACC AGT T-3′; antisense:5′- CCA GGG TTC CCC TTC TGA CT-3′) and reference gene Ciclophilin (Sense: 5′- TGG CAA GCA TGT TGG GTC TTT GGG AAG-3′; antisense: 5′-GGT GAT CTT CTT GCT GCT CTG CCA TTC-3′). Real-time PCRs were run separately, and amplifications were performed by ABI Prism 5700 Sequence Detection System (Applied Biosystems, USA) by using SYBR Green PCR Master Mix (Applied Biosystems, USA). Results were quantified as Ct values, where Ct is defined as the threshold cycle of the polymerase chain reaction at which the amplified product is first detected. Each sample was analyzed in duplicate. Relative quantities of target gene expressions of four groups were compared after normalization to the values of the reference gene (ΔCT). Fold changes in mRNA expression were calculated using the differences in ΔCT values between the two samples (ΔΔCT) and the equation 2-ΔΔCT. Results are expressed in percentages of control (Sham-S).
Results are presented as mean±SEM. The Student t test was conducted to compare infarcted and Sham rats 4 weeks after surgery and, hence, ascertain for CHF. At the end of the protocol (12 weeks after surgery), the groups were compared by 2-way ANOVA (exercise training and CHF as the main factors), with Scheffé test for post hoc comparisons. P value ≤ 0.05 was accepted as significant.
Four weeks after surgery, body weight was not significantly different between CHF and Sham rats (386±15 vs. 377±11.7 g). Left ventricular end-diastolic diameter (EDD), end-systolic diameter (ESD), fractional shortening (FS), and ejection fraction (EF) were significantly lower in CHF rats compared with that of Sham rats, consistent with cardiac remodeling associated with dilation and dysfunction (Table 1). Functional capacity, expressed by peak VO2, and running distance were lower in the CHF rats, indicating exercise intolerance (Table 1). At this point, the rats were divided into sedentary and exercise-trained groups.
Effects of Exercise Training on Functional Capacity and Cardiac Function
Physiological parameters in untrained and exercised-trained Sham and CHF rats are shown in Table 2. There were no significant differences in body weight among groups. The heart and right ventricle mass were significantly increased in CHF rats, and exercise training caused no changes in these parameters (Table 2). Exercise training did not significantly change echocardiographic parameters or peak VO2 in CHF rats. However, exercise training significantly increased running distance in both Sham-operated and CHF rats but caused no change in FS (Fig. 2).
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained. A, Fractional shortening (FS); B, Running distance in Sham and CHF, sedentary and trained rats, 12 week after surgery. *P<0.05 vs. Sham-S; †P<0.05 vs. CHF-S.
Effects of Exercise Training on Circulating RAS
CHF did not change serum ACE activity, but caused a 25% reduction in ACE2 activity (Fig. 3, P = 0.04). Exercise training significantly decreased ACE activity in the CHF rats (P = 0.05), and restored the ACE2 activity towards the levels found in Sham-operated rats (Fig. 3). No significant changes in ACE and ACE2 activity occurred in the Sham-Ex. In regard to plasma angiotensins, we found no significant changes in plasma AngII levels in CHF rats. Exercise training provoked a significant reduction in AngII levels in both Sham (33%, P = 0.03) and CHF rats (43%, P = 0.007) (Fig. 3). Plasma AngI and Ang-(1–7) were unchanged by CHF or exercise training (Table 3 and Fig. 3). However, exercise training significantly increased the Ang-(1–7)/AngII ratio in CHF rats (Fig. 3). No changes were found in the Sham-Ex.
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained. A, Angiotensin II; B, Angiotensin-(1–7); C, Ang-(1–7)/AngII ratio; D, ACE activity; E, ACE2 activity. *P<0.05 vs. Sham-S; †P<0.05 vs. CHF-S.
Effects of Exercise Training on RAS in the Soleus Muscle
CHF or exercise training did not change ACE activity and protein expression in soleus muscle (Fig. 4). CHF provoked a 2.1-fold increase in AngII concentration in the soleus muscle (P = 0.001), and exercise training decreased it to the normal levels (Fig. 5). There were no significant differences in AngI among groups (Table 3). The AT1 receptor gene expression in the soleus muscle was significantly increased in CHF rats (P = 0.04, Fig. 6). Exercise training normalized these levels. AT2 gene expression was not different among groups. Similarly, no changes in Ang-(1–7) concentration were found among groups (Fig. 5). Exercise training tended to increase Ang-(1–7)/AngII ratio in Sham-operated (P = 0.06) and CHF (P = 0.08) rats (Fig. 5). Exercise training increased Mas gene expression in both Sham and CHF rats (P = 0.02) (Fig. 6).
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained; ACE, Angiotensin Converting Enzyme. A, ACE activity; B, ACE2 activity; C, ACE protein expression; D, ACE2 protein expression.
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained. A, Angiotensin II; B, Angiotensin-(1–7); C, Ang-(1–7)/AngII ratio. *P<0.05 vs. Sham-S.
Effects of Exercise Training on RAS in Plantaris Muscle
In regard to plantaris muscle, CHF and exercise training unchanged ACE activity and protein expression (Fig. 7). In contrast, AngI and AngII in the plantaris muscle were 1.5- and 2.5-fold increased of CHF rats (Table 3, Fig. 8). CHF and exercise training did not change AT1 or AT2 receptors (Fig. 9). Exercise training decreased AngI and AngII towards normal levels (Table 3, Fig. 8). Exercise training significantly increased Ang-(1–7), but caused no significant changes in Ang-(1–7)/AngII ratio (Fig. 8). There were no differences in ACE2 activity or protein expression among groups (Fig. 7). Exercise training significantly reduced the Mas gene expression in CHF (Fig. 9).
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained; ACE, Angiotensin Converting Enzyme. A, ACE activity; B, ACE2 activity; C, ACE protein expression; D, ACE2 protein expression.
CHF, chronic heart failure; -S, Sedentary; -Ex, Exercise-trained. A, Angiotensin II; B, Angiotensin-(1–7); C, Ang-(1–7)/AngII ratio. *P<0.05 vs. Sham-S.
The main and new findings of the present study are that exercise training in an ischemic model of CHF: 1) Normalizes AngII concentration in soleus and plantaris muscle; 2) Decreases AT1 receptors towards normal levels in soleus muscle; 3) Increases Ang-(1–7)/AngII ratio in plasma and soleus; and 4) Increases Mas receptor mRNA expression in soleus muscle.
Our study confirms previous studies ,  that demonstrated that exercise training causes remarkable changes in circulating RAS in CHF. The reduction in circulating ACE activity and AngII concentration in CHF rats has important implications. Firstly, the improvement in arterial baroreflex control of renal sympathetic nerve activity in CHF rats depends on the reduction in plasma AngII . Mousa and collaborators  elegantly demonstrated that administration of AngII to maintain its levels near those found in untrained CHF restrained the amelioration in arterial baroreflex sensitivity in exercise-trained CHF rabbits. Secondly, AngII increases sympathetic nerve activity , . This knowledge may predict that exercise training decreased sympathetic outflow in our study. In fact, sympathetic deactivation has been consistently reported after exercise training in CHF , , . Thirdly, both the improvement in baroreflex sensitivity and the reduction in sympathetic activity are associated with better prognosis in CHF , .
In CHF patients, there is an association between serum ACE2 and the severity of this syndrome . A possible explanation for this response is that AngII provokes ACE2 shedding mediated by TACE/ADAM-17, which increases serum ACE2 activity . In conformity to a previous study on the same experimental model , we found that serum ACE2 activity was reduced in CHF. The contrast between serum ACE2 in humans with CHF and the experimental model of CHF is not clear. However, it could be speculated that the pharmacological inhibition of ACE usually prescribed for humans with CHF causes a compensatory increase in serum ACE2 activity. In fact, some investigators have previously observed an association between serum ACE inhibition and ACE2 increase . Exercise training significantly decreased serum ACE activity and increased serum ACE2 activity. This finding reinforces the inverse association between ACE and ACE2 activity.
Despite the fact that exercise training increases serum ACE2 activity towards normal levels, no significant changes in circulating Ang-(1–7) concentration were found. Since AngII is the major substrate for the production of Ang-(1–7), it is possible to anticipate that the reduction in AngII concentration limited the formation of Ang-(1–7). All together, these findings indicate that exercise training causes a switch in circulating ACE-AngII towards an increase in ACE2-Ang-(1–7) axis in CHF rats, which may render the cardiovascular system less susceptible to the deleterious actions of AngII .
We hypothesized that exercise training would cause a shift in RAS in skeletal muscle towards the ACE2-Ang-(1–7)-Mas axis. Our findings confirm in great part this hypothesis. Exercise training decreased AngII in both soleus and plantaris muscle in the ischemic model of CHF. In addition, exercise training tended to increase the Ang-(1–7)/AngII ratio, which suggests an imbalance in the RAS towards the ACE2-Ang-(1–7)-Mas receptor axis. The reduction in the AngII concentration and AT1 receptor gene expression in skeletal muscle is an important issue. Previous studies show that AngII is involved in inflammation and oxidative stress , . These alterations contribute to muscle catabolism and apoptosis in CHF –, , . Our study provides no information on muscle protein synthesis and degradation. Future investigations should focus on the contribution of ACE-AngII-AT1 receptor axis in the amelioration in skeletal myopathy.
The mechanisms by which exercise training decreased AngII concentration in skeletal muscle in CHF rats is out of the scope of the present study. However, it is possible that exercise training reduced AngII uptake in the soleus muscle , because AT1 expression was substantially lower in the exercise-trained rats. In plantaris muscle, exercise training also reduced AngII concentration, but caused no changes in AT1 expression. These findings raise the question that the mechanisms underlying the reduction in AngII in plantaris muscle and soleus muscle are different. Someone could suggest that the reduction in AngII in the plantar muscle is due to the decrease in AngI cleavage. In fact, we found that AngI concentration in plantar muscle was significantly lower in exercise-trained CHF compared to that in untrained CHF rats.
Our data clearly demonstrate that there is a mismatch between circulating and skeletal muscle RAS. Elevation in AngII concentration was found in the skeletal muscle, but not in the circulation. These findings are consistent with those of previous studies that show that local RAS becomes activated in tissues in CHF –. The increase in the plasma AngII concentration seems to occur only in the late stage of CHF , . ACE was not altered in the skeletal muscle, which suggests alternative local pathways of AngII production involving other enzymes as Prolyl-endopeptidase, Neprilysin and Chymase –, especially in the plantaris muscle. Exercise training reduced AngII concentration in both plasma and skeletal muscle. Exercise training reduces ACE and restores ACE2 activity in the circulation, without changing ACE and ACE2 activity or protein expression in skeletal muscle. Other investigators reported that electric stimulated C2C12, a strategy to mimic in vitro exercise effects, caused no changes in skeletal muscle ACE gene expression .
Previous studies demonstrated that the AT1 receptor was increased in the vasculature of patients with ischemic heart disease , and in local tissues in experimental models of CHF , , . In our study, we found increased AT1 receptor mRNA in soleus muscle in CHF rats. This increase in AT1 receptors may be associated with elevation in sympathetic nerve activity. In a previous study, isoproterenol administration increased AT1 receptor expression . Exercise training reverted AT1 receptor gene expression towards normal levels, which may be linked to reduction in sympathetic activation. We and others have consistently found a reduction in sympathetic nerve activity in heart failure , , .
We found no changes in AT2 receptors in our study. The AT2 gene expression in both soleus and plantar muscles was not altered in CHF rats. Similar findings have been reported in patients with heart failure. Some investigators found no AT2 gene expression in skeletal muscle in patients with CHF . In our study, exercise training caused no changes in AT2 receptors in either normal controls or CHF rats.
Our study demonstrates for the first time that exercise training changes the Ang-(1–7) and Ang-(1–7)/AngII ratio and Mas receptor expression in skeletal muscle in CHF rats. These are remarkable effects provoked by exercise training. Ang-(1–7) is a potent vasodilator as are other interventions in the treatment of heart failure, and in the muscle level, Ang-(1–7)/Mas improves insulin sensitivity by increasing Akt phosphorilation .
We recognize limitations in our study. We only studied mRNA expression of angiotensin receptors. Thus, someone could argue that there is no guarantee that the changes in gene expression have been translated into protein expression. Our study provides no direct information regarding the implications of RAS modifications in the function of skeletal muscle. The increase in running distance is suggestive of improvement in functional capacity, but not sufficient to demonstrate amelioration in skeletal muscle function.
The antagonism of the RAS and sympathetic outflow is the target in the treatment of heart failure. The present study shows that exercise training provokes profound changes in circulating and skeletal muscle RAS. The switch from AngII/AT1 to Ang-(1–7)/Mas axis in the skeletal muscle may have implications in the skeletal myopathy in heart failure. Growing evidence shows that AngII is involved in the skeletal muscle pathophysiology of heart failure. Finally, these findings strengthen the recommendation of exercise training in the treatment of CHF.
In conclusion, exercise training improves RAS in the Ang-(1–7)-Mas axis in skeletal muscle. This effect of exercise training seems to depend on skeletal muscle metabolic characteristics. The changes in circulating RAS do not necessarily reflect the changes occurring in skeletal muscle RAS.
Conceived and designed the experiments: ILGS EMdO CEN. Performed the experiments: ILGS TF GKC FBF VMCS. Analyzed the data: ILGS TF DEC FBF JCAFF. Contributed reagents/materials/analysis tools: PCB DEC LVR EMdO CEN. Wrote the paper: ILGS CEN.
- 1. Sigurdsson A, Held P, Swedberg K (1993) Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126: 1068–1076.
- 2. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P (1985) Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 72: 406–412.
- 3. Kato M, Kinugawa T, Omodani H, Osaki S, Ahmmed GU, et al. (1996) Responses of plasma norepinephrine and renin-angiotensin-aldosterone system to dynamic exercise in patients with congestive heart failure. J Card Fail 2: 103–110.
- 4. Roig E, Perez-Villa F, Morales M, Jiménez W, Orús J, et al. (2000) Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 21: 53–57.
- 5. Xu X, Wan W, Ji L, Lao S, Powers AS, et al. (2008) Exercise training combined with angiotensin II receptor blockade limits post-infarct ventricular remodelling in rats. Cardiovasc Res 78: 523–532.
- 6. Ferreira JCB, Bacurau A V, Evangelista FS, Coelho MA, Oliveira EM, et al. (2008) The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Am J Physiol Regul Integr Comp Physiol 294: R26–32.
- 7. Kar S, Gao L, Zucker IH (2010) Exercise training normalizes ACE and ACE2 in the brain of rabbits with pacing-induced heart failure. J Appl Physiol 108: 923–932.
- 8. Schunkert H, Ingelfinger JR, Hirsch a T, Tang SS, Litwin SE, et al. (1992) Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90: 1523–1529.
- 9. Pfeffer JM, Pfeffer MA, Braunwald E (1985) Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84–95.
- 10. Mousa TM, Liu D, Cornish KG, Zucker IH (2008) Exercise training enhances baroreflex sensitivity by an angiotensin II-dependent mechanism in chronic heart failure. J Appl Physiol 5850: 616–624.
- 11. Abassi ZA, Gurbanov K, Mulroney SE, Potlog C, Opgenorth TJ, et al. (1997) Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II. Circulation 96: 3655–3664.
- 12. Dalla Libera L, Ravara B, Angelini A, Rossini K, Sandri M, et al. (2001) Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure. Circulation 103: 2195–2200.
- 13. Russell ST, Eley H, Tisdale MJ (2007) Role of reactive oxygen species in protein degradation in murine myotubes induced by proteolysis-inducing factor and angiotensin II. Cell Signal 19: 1797–1806.
- 14. Semprun-Prieto LC, Sukhanov S, Yoshida T, Rezk BM, Gonzalez-Villalobos RA, et al. (2011) Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochem Biophys Res Commun 409: 217–221.
- 15. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, et al. (2000) A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circ Res 87: e1–e9.
- 16. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, et al. (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238–33243.
- 17. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, et al. (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838–14843.
- 18. Santos RAS, Simoes e Silva AC, Maric C, Silva DMR, Machado RP, et al. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100: 8258–8263.
- 19. Prasannarong M, Santos FR, Henriksen EJ (2012) Ang-(1–7) reduces Ang II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle. Biochem Biophys Res Commun 426: 369–373.
- 20. Muñoz MC, Giani JF, Burghi V, Mayer MA, Carranza A, et al. (2012) The Mas receptor mediates modulation of insulin signaling by angiotensin-(1–7). Regul Pept 177: 1–11.
- 21. Santos RAS, Ferreira AJ, Verano-Braga T, Bader M (2013) Angiotensin-converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216: R1–R17.
- 22. Negrao CE, Middlekauff HR (2008) Adaptations in autonomic function during exercise training in heart failure. Heart Fail Rev 13: 51–60.
- 23. Roveda F, Middlekauff HR, Rondon MU, Reis SF, Souza M, et al. (2003) The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol 42: 854–860.
- 24. De Mello Franco FG, Santos AC, Rondon MUP, Trombetta IC, Strunz C, et al. (2006) Effects of home-based exercise training on neurovascular control in patients with heart failure. Eur J Heart Fail 8: 851–855.
- 25. Braith RW, Welsch MA, Feigenbaum MS, Kluess HA, Pepine CJ (1999) Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol 34: 1170–1175.
- 26. Fernandes T, Hashimoto NY, Magalhães FC, Fernandes FB, Casarini DE, et al. (2011) Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1–7). Hypertension 58: 182–189.
- 27. Filho AG, Ferreira AJ, Santos SHS, Neves SRS, Silva Camargos ER, et al. (2008) Selective increase of angiotensin(1–7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training. Exp Physiol 93: 589–598.
- 28. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, et al. (2010) A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res 107: 1445–1453.
- 29. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiograph. J Am Soc Echocardiogr 18: 1440–1463.
- 30. Brooks GA, White TP (1978) Determination of metabolic and heart rate responses of rats to treadmill exercise. J Appl Physiol 45: 1009–1015.
- 31. Rondon E, Brasileiro-Santos MS, Moreira ED, Rondon MUPB, Mattos KC, et al. (2006) Exercise training improves aortic depressor nerve sensitivity in rats with ischemia-induced heart failure. Am J Physiol Heart Circ Physiol 291: H2801–6.
- 32. Fernandes T, Hashimoto NY, Oliveira EM (2010) Characterization of angiotensin-converting enzymes 1 and 2 in the soleus and plantaris muscles of rats. Braz J Med Biol Res 43: 837–842.
- 33. Liu JL, Irvine S, Reid IA, Patel KP, Zucker IH (2000) Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: A role for angiotensin II. Circulation 102: 1854–1862.
- 34. Barretto ACP, Santos AC, Munhoz R, Rondon MU, Franco FG, et al. (2009) Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 135: 302–307.
- 35. Osterziel KJ, Hänlein D, Willenbrock R, Eichhorn C, Luft F, et al. (1995) Baroreflex sensitivity and cardiovascular mortality in patients with mild to moderate heart failure. Br Heart J 73: 517–522.
- 36. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, et al. (2008) Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol 52: 750–754.
- 37. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, et al. (2014) Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J Mol Cell Cardiol 66: 167–176.
- 38. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, et al. (2006) Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48: 572–578.
- 39. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, et al. (2006) Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 29: 865–874.
- 40. Ferrario CM (2011) ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens 20: 1–6.
- 41. Mariappan N, Elks CM, Haque M, Francis J (2012) Interaction of TNF with angiotensin II contributes to mitochondrial oxidative stress and cardiac damage in rats. PLoS One 7: e46568.
- 42. Vescovo G, Volterrani M, Zennaro R, Sandri M, Ceconi C, et al. (2000) Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 84: 431–437.
- 43. Burniston JG, Saini A, Tan L-B, Goldspink DF (2005) Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Exp Physiol 90: 755–761.
- 44. Van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, et al. (1997) Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30: 42–49.
- 45. Uehara Y, Miura S, Yahiro E, Saku K (2013) Non-ACE pathway-induced angiotensin II production. Curr Pharm Des 19: 3054–3059.
- 46. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, et al. (1998) Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32: 514–520.
- 47. Ward PE, Russell JS, Vaghy PL (1995) Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. Peptides 16: 1073–1078.
- 48. Johnston APW, Baker J, De Lisio M, Parise G (2011) Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J Renin Angiotensin Aldosterone Syst 12: 75–84.
- 49. Dimitrijevic I, Edvinsson M-L, Chen Q, Malmsjö M, Kimblad P-O, et al. (2009) Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovasc Disord 9: 40.
- 50. Zhang G-X, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, et al. (2007) Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 42: 804–811.
- 51. Malendowicz SL, Ennezat P V, Testa M, Murray L, Sonnenblick EH, et al. (2000) Angiotensin II receptor subtypes in the skeletal muscle vasculature of patients with severe congestive heart failure. Circulation 102: 2210–2213.